Sandbox Reserved 911: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA, R. Jeremy Johnson, Rachel Erkilla, Melissa Jones

Revision as of 19:30, 21 April 2014 view source Rachel Erkilla (talk \| contribs) 92 edits No edit summary ← Older edit		Latest revision as of 02:29, 22 April 2014 view source Melissa Jones (talk \| contribs) 97 edits No edit summary
Line 29:		Line 29:

	FAAH plays a role in endocannabinoid signaling that has intriguing potential as a drug target. This signaling system consists of endocannabinoid ligands (such as AEA), two G protein-coupled receptors (CB1 and CB2), and the enzymes that synthesize and degrade (such as FAAH) the signaling lipids. Previous research has explored the potential of regulating endocannabinoid signaling through the CB1 and CB2 receptors. However, molecules found to activate these receptors (such as [http://www.ch.ic.ac.uk/vchemlib/mim/bristol/thc/thc_text.htm tetrahydrocannabinol] (THC), the main psychoactive ingredient of [http://en.wikipedia.org/wiki/Cannabis_(drug) marijuana]), while providing the intended pain relief, also produce many undesirable side effects, such as decreased cognition and motor control. On the other hand, research involving FAAH inhibitors has shown that blocking this part of the pathway reduces pain without the unwanted side effects seen through CB1/CB2 activation. Thus, exploring the possibility of using FAAH inhibition to decrease pain relief with minimal side effects could lead to new pain treatment solutions. For example, the [http://drugdiscoveryopinion.com/2009/04/pf-3845-%E2%80%93-a-potent-and-selective-faah-inhibitor/ PF-3845 inhibitor]of FAAH is extremely selective for the enzyme and raises AEA levels for a prolonged duration of time. Therefore, this inhibitor could be explored as a possible pharmaceutical product to target FAAH when extended pain relief is desired <ref name="2WAP"/>.		FAAH plays a role in endocannabinoid signaling that has intriguing potential as a drug target. This signaling system consists of endocannabinoid ligands (such as AEA), two G protein-coupled receptors (CB1 and CB2), and the enzymes that synthesize and degrade (such as FAAH) the signaling lipids. Previous research has explored the potential of regulating endocannabinoid signaling through the CB1 and CB2 receptors. However, molecules found to activate these receptors (such as [http://www.ch.ic.ac.uk/vchemlib/mim/bristol/thc/thc_text.htm tetrahydrocannabinol] (THC), the main psychoactive ingredient of [http://en.wikipedia.org/wiki/Cannabis_(drug) marijuana]), while providing the intended pain relief, also produce many undesirable side effects, such as decreased cognition and motor control. On the other hand, research involving FAAH inhibitors has shown that blocking this part of the pathway reduces pain without the unwanted side effects seen through CB1/CB2 activation. Thus, exploring the possibility of using FAAH inhibition to decrease pain relief with minimal side effects could lead to new pain treatment solutions. For example, the [http://drugdiscoveryopinion.com/2009/04/pf-3845-%E2%80%93-a-potent-and-selective-faah-inhibitor/ PF-3845 inhibitor]of FAAH is extremely selective for the enzyme and raises AEA levels for a prolonged duration of time. Therefore, this inhibitor could be explored as a possible pharmaceutical product to target FAAH when extended pain relief is desired <ref name="2WAP"/>.